Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.

Research paper by Ying Y Shi, Tong T Cao, Hua H Huang, Chaoqun C Lian, Ying Y Yang, Zhiwei Z Wang, Jia J Ma, Jun J Xia

Indexed on: 06 Oct '17Published on: 06 Oct '17Published in: Cell cycle (Georgetown, Tex.)


Arsenic trioxide (ATO) has been reported to exert its anti-cancer activities in human cancers. However, the molecular mechanism of ATO-triggered anti-tumor activity has not been fully elucidated. Recently, multiple studies demonstrated that ATO could regulate miRNAs in human cancers. Therefore, in this study, we investigated whether ATO regulated let-7a in breast cancer cells. We found that ATO upregulated let-7a level in breast cancer cells. We also found that up-regulation of let-7a inhibited cell growth and induced apoptosis and retarded cell migration and invasion. We also observed that up-regulation of let-7a enhanced cell growth inhibition and invasion suppression induced by ATO treatment. Our findings suggest that ATO suppressed cell growth, stimulated apoptosis, and retarded cell invasion partly via upregulation of let-7a in breast cancer cells. Our study provides a new anti-tumor mechanism of ATO treatment in breast cancer.